Formycon AG (LON:0W4N)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 289.24M -26.8% |
| Revenue (ttm) | 52.73M +18.3% |
| Net Income | -21.64M |
| EPS | -1.22 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 491 |
| Open | 19.40 |
| Previous Close | 18.96 |
| Day's Range | 18.92 - 19.40 |
| 52-Week Range | 15.90 - 26.85 |
| Beta | 0.72 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis... [Read more]
Financial Performance
In 2025, Formycon AG's revenue was 44.48 million, a decrease of -36.17% compared to the previous year's 69.67 million. Losses were -64.70 million, -48.52% less than in 2024.
Financial numbers in EUR Financial StatementsNews
Formycon AG Earnings Call Transcript: Q2 2026
H1 2026 saw revenues nearly triple year-over-year, driven by strong commercialization of FYB202 and FYB206, with adjusted EBITDA improving significantly. The outlook remains positive with further revenue growth expected from FYB202 royalties and milestone payments for FYB206, while the company maintains a strong equity ratio and continues to invest in its pipeline.
Formycon AG Quarterly report: Q2 2026
Formycon AG has published its Q2 2026 quarterly earnings report on August 12, 2026.
Formycon AG Earnings release: Q2 2026
Formycon AG released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Formycon AG Slides: Q2 2026
Formycon AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
EQS-News: Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year
EQS-News: Formycon AG / Key word(s): Half Year Results/Half Year Report Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-yea...
EQS-News: Formycon invites to conference call on 2026 half-year results and announces participation in international investor conferences
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon invites to conference call on 2026 half-year results and announces participation in international investor conferences 05.08.2026 / 06:30 CE...
EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Formycon AG / Preliminary announcement on the disclosure of financial statements Formycon AG: Preliminary announcement of the publication of financial r...
EQS-News: Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars 14.07.2026 / 06:30 CET/CEST The issuer is sol...
EQS-News: Formycon AG Reports Results of Annual General Meeting 2026
EQS-News: Formycon AG / Key word(s): AGM/EGM Formycon AG Reports Results of Annual General Meeting 2026 10.06.2026 / 16:22 CET/CEST The issuer is solely responsible for the content of this announcemen...
Formycon AG Transcript: Jefferies Global Healthcare Conference 2026
The company is accelerating its biosimilar portfolio, with three products launched and several more in advanced stages. Regulatory changes and strategic regional partnerships are driving growth, with revenue and profitability targets set for 2026.
Formycon AG Earnings Call Transcript: Q1 2026
Q1 2026 saw revenues more than double year-over-year, driven by FYB202 and FYB206, with EBITDA losses narrowing sharply. Key launches and partnerships expanded the commercial portfolio, and guidance for 2026 is confirmed, with growth expected from milestone achievements and royalties.
Formycon AG Earnings release: Q1 2026
Formycon AG released its Q1 2026 earnings on May 28, 2026, summarizing the period's financial results.
Formycon AG Slides: Q1 2026
Formycon AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 28, 2026.
EQS-News: Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026
EQS-News: Formycon AG / Key word(s): Quarterly / Interim Statement/Quarter Results Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026 28.05.2026 / 06...
EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Formycon AG / Preliminary announcement on the disclosure of financial statements Formycon AG: Preliminary announcement of the publication of quarterly r...
EQS-News: Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences 21....
EQS-News: Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive and Baiama are now available in the European Union
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive and Baiama are now available in the European Union 19.05.2026 / 06:30 CET/CE...
Formycon AG Earnings Call Transcript: Q4 2025
2025 saw a strategic transformation with improved adjusted EBITDA and strong cost management, despite lower revenues. 2026 guidance anticipates significant revenue growth, driven by FYB202 royalties and FYB206 milestones, with positive EBITDA expected.
Formycon AG Annual report: Q4 2025
Formycon AG has published its Q4 2025 annual report on April 22, 2026.
Formycon AG Annual report: Q4 2025
Formycon AG has published its Q4 2025 annual report on April 22, 2026.
Formycon AG Earnings release: Q4 2025
Formycon AG released its Q4 2025 earnings on April 22, 2026, summarizing the period's financial results.
EQS-News: Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships
EQS-News: Formycon AG / Key word(s): Annual Report/Forecast Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships 22.0...
EQS-News: Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in th...
EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Formycon AG / Preliminary announcement on the disclosure of financial statements Formycon AG: Preliminary announcement of the publication of financial r...
Formycon AG: Unlocking Breakthrough Biotech Innovations
The company reports a marked EBITDA recovery, stable revenues, and higher working capital, while confirming its FYB202 assessment and setting the stage for the 2026 outlook.